Sort
48,018 grants matching “immunotherapy”
Enzymology of Mismatch Repair in Yeast
$406,850Richard D Kolodner · University Of California, San Diego · R01 · FY2025 · GM
Enzymology of Mismatch Repair in Yeast
$406,850Richard D Kolodner · University Of California, San Diego · R01 · FY2024 · GM
Enzymology of Mismatch Repair in Yeast
$406,850Richard D Kolodner · University Of California, San Diego · R01 · FY2023 · GM
Functional Activation of Low Affinity TILs
$406,837Jill E Slansky · University Of Colorado Denver · R01 · FY2022 · CA
Antibody Gene Therapy for Methamphetamine Abuse
$406,795Eric C Peterson · Univ Of Arkansas For Med Scis · R01 · FY2017 · DA
ALLOGENIC PANCREATIC TUMOR VACCINE CELL LINE
$406,745Johns Hopkins University · R01 · FY2001 · CA
Binding and Presentation of Lipid Antigens by CD1
$406,742Steven A Porcelli · Albert Einstein College Of Medicine · R01 · FY2011 · AI
Binding and Presentation of Lipid Antigens by CD1
$406,742Steven A Porcelli · Albert Einstein College Of Medicine · R01 · FY2012 · AI
A Glycopeptide from Interstitial Cystitis Patients as a Novel Anticancer Lead
$406,632Joseph John Barchi · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
IDO1 and Immunotolerance in Glioblastoma
$406,629Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2019 · NS
Controlled Release of Macromolecules
$406,614Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2009 · EB
Immune cell control of ovarian cancer
$406,610Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Neuroimmunology of Malignant Brain Tumors: Innate Mechanisms
$406,525Pedro R Lowenstein · University Of Michigan At Ann Arbor · R01 · FY2016 · NS
Rapid and Automated Dissociation of Tumor Tissue for Single Cell Diagnostics
$406,500Ahmed Nabil Zobi · Syntr Health Technologies, Llc · R43 · FY2025 · TR
Direct Activation of PP2A as a Novel Approach to Group-3 Medulloblastoma Therapy
$406,500Michael Ohlmeyer · Atux Iskay Group Llc · R43 · FY2022 · CA
Enhancing Solid Tumor lmmunotherapy with Targeted siRNA Delivery
$406,500David H Altreuter · Absco Therapeutics, Inc. D/B/A Abscotx · R43 · FY2025 · CA
HLA LOH Detection via Liquid Biopsy: A Blood-Based Predictive Biomarker Assay for Precision Immuno-Oncology
$406,500Andrew Sinkoe · Sesh Incorporated · U43 · FY2025 · CA
Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications
$406,500Connie S Lebakken · Stem Pharm, Inc. · R41 · FY2023 · CA
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
$406,500Ozgur Sahin · Loxigen, Inc. · R42 · FY2023 · CA
Core D: Pathology and BioImaging
$406,464Carl D Morrison · Roswell Park Cancer Institute Corp · P01 · FY2020 · CA
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
$406,375Yibin Yang · Research Inst Of Fox Chase Can Ctr · R01 · FY2024 · CA
Dissecting the pathways controlling tunable responses to TCR signaling
$406,354Leslie J. Berg · University Of Colorado Denver · R01 · FY2020 · AI
The integrated stress response and the microenvironment in melanoma progression
$406,333Constantinos Koumenis · University Of Pennsylvania · R01 · FY2023 · CA
Eastern Cooperative Oncology Group Studies
$406,274Case Western Reserve University · U10 · FY2005 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
$406,274Xiang-Yang Wang · Virginia Commonwealth University · R01 · FY2022 · CA